Literature DB >> 6726306

Charts for the early stopping of pilot studies.

C R Mehta, K C Cain.   

Abstract

Cooperative oncology groups usually run pilot studies of new agents or combinations concurrently with their major randomized clinical trials. A primary objective of these studies is to determine whether the new regimen should be tested further in a group-wide clinical trial. The accrual goals of such pilot studies are typically fixed in advance at between 30 and 40 patients, on the grounds that this number provides a reasonably tight confidence interval on the true response rate. Nevertheless early termination of pilot studies is often desirable either because the regimen appears inactive or because early results indicate extreme activity and justify immediate testing in a randomized study. Statistical charts are provided for early termination in both these situations. The charts are read by specifying the number of evaluable patients already accrued, the number of responses observed and the minimum true response rate, theta 0, at which the regimen would be considered active. The charts provide the posterior probability that the true response rate exceeds theta 0, that is, that the regimen is active. An additional chart that computes a 90% probability interval for the true response rate, based on the observed rate and sample size, is also provided. The use of the chart is illustrated with two examples from the Eastern Cooperative Oncology Group.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6726306     DOI: 10.1200/JCO.1984.2.6.676

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  4 in total

1.  Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints.

Authors:  Wei Jiang; Jo A Wick; Jianghua He; Jonathan D Mahnken; Matthew S Mayo
Journal:  J Biopharm Stat       Date:  2017-11-27       Impact factor: 1.051

2.  Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial.

Authors:  L E Stenbygaard; J Herrstedt; J F Thomsen; K R Svendsen; S A Engelholm; P Dombernowsky
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

3.  A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol.

Authors:  Sina Vatandoust; David Wattchow; Luigi Sposato; Michael Z Michael; John Leung; Kirsten Gormly; Gang Chen; Erin L Symonds; Jeanne Tie; Lito Electra Papanicolas; Susan Woods; Val Gebski; Kelly Mead; Aleksandra Kuruni; Christos S Karapetis
Journal:  BMC Cancer       Date:  2022-03-01       Impact factor: 4.430

4.  Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial.

Authors:  Paolo Zamboni; Antonio Bertolotto; Paolo Boldrini; Patrizia Cenni; Roberto D'Alessandro; Roberto D'Amico; Massimo Del Sette; Roberto Galeotti; Stefania Galimberti; Alessandro Liberati; Luca Massacesi; Donato Papini; Fabrizio Salvi; Silvana Simi; Andrea Stella; Luigi Tesio; Maria Grazia Valsecchi; Graziella Filippini
Journal:  Trials       Date:  2012-10-03       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.